On June 9, 2026, a significant agreement was forged between the Emirates Drug Corporation and Novo Nordisk, marking a pivotal step toward innovating the pharmaceutical industry in the UAE. This collaboration aims to boost the development of pharmaceutical products through advanced training, research support, and the expedited introduction of modern therapies. The memorandum of understanding highlights a commitment to creating a sustainable and progressive pharmaceutical ecosystem that fosters innovation and enhances local capabilities.
The Emirates Drug Corporation signed a memorandum of understanding with the global company Novo Nordisk, aimed at strengthening cooperation in the field of pharmaceutical product manufacturing using the latest technologies and promoting an advanced and sustainable pharmaceutical system that supports innovation. The agreement includes programs for capacity building and the development of national competencies through training initiatives, knowledge exchange, and professional qualification pathways, alongside involving national personnel and students in academic and practical programs within the pharmaceutical work environment.
In the area of innovation and research and development, the memorandum includes the establishment of a supportive regulatory environment to accelerate the introduction of modern therapies and expand access opportunities, in addition to enhancing the participation of institutions and stakeholders in the UAE in product development projects and research related to the company’s activities.
This agreement is considered a strategic step toward achieving excellence in the healthcare sector, as it contributes to raising local competencies and enhancing a culture of innovation. The training programs outlined in the memorandum serve as an interactive platform empowering national personnel to acquire new skills that meet market needs.
Furthermore, the memorandum of understanding between the Emirates Drug Corporation and Novo Nordisk will focus on enhancing collaboration between academic institutions and the industrial sector. This will enable educational institutions to equip students with the necessary and practical knowledge, leading to greater involvement in real projects and creating new job opportunities in this vital field.
Thanks to these joint efforts, the memorandum of understanding between the Emirates Drug Corporation and Novo Nordisk is expected to have a significant impact on improving the quality of healthcare in the country by providing modern and effective medications to the public. The collaboration between government bodies and global companies, as evidenced by this agreement, represents a model to be emulated in achieving the goals of the UAE’s sustainable health vision.